$18.75 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter

Brokerages forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will post sales of $18.75 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $5.20 million and the highest estimate coming in at $32.29 million. Inovio Pharmaceuticals reported sales of $6.20 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 202.4%. The firm is scheduled to report its next earnings results after the market closes on Tuesday, August 8th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year sales of $18.75 million for the current financial year, with estimates ranging from $25.98 million to $78.12 million. For the next fiscal year, analysts forecast that the company will report sales of $19.81 million per share, with estimates ranging from $18.82 million to $20.80 million. Zacks’ sales averages are an average based on a survey of analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. During the same period in the prior year, the firm posted ($0.11) EPS. The company’s quarterly revenue was up 28.4% on a year-over-year basis.

INO has been the topic of several analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $11.00 target price on shares of Inovio Pharmaceuticals in a research note on Thursday, May 25th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research note on Tuesday, July 11th. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, June 8th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, June 9th. Finally, ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $19.90.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the transaction, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.60% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 62,045 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after buying an additional 11,765 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 16,845 shares during the last quarter. Finally, Stoneridge Investment Partners LLC increased its position in shares of Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 2,073 shares during the last quarter. 22.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “$18.75 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/19/18-75-million-in-sales-expected-for-inovio-pharmaceuticals-inc-ino-this-quarter-updated-updated.html.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.56 on Tuesday. Inovio Pharmaceuticals has a 1-year low of $5.50 and a 1-year high of $11.00. The stock has a 50 day moving average of $7.45 and a 200-day moving average of $6.88. The company’s market capitalization is $414.93 million.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Inovio Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inovio Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit